There are currently two ongoing trials (phase 2 and 3) evaluating T-DXd as a first-line treatment in metastatic HER-2-positive breast cancer and one study evaluating it as a first-line treatment in HER-2-low patients (see Table 4). Here, ERBB2 is linked to breast carcinoma.